Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Ford Investor Services, Inc.
$12.00
Provider: Jefferson Research
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

GlaxosmithKline Plc and Genmab announce top-line results from Phase III study of ofatumumab versus physicians' choice for bulky fludarabine-refractory CLL


Friday, 27 Jun 2014 02:27pm EDT 

GlaxosmithKline Plc:Says the company and Genmab A/S announced Phase III study of ofatumumab (Arzerra) versus physicians' choice in patients with bulky fludarabine-refractory chronic lymphocytic leukaemia (CLL) did not meet its primary endpoint of progression free survival.Says the median PFS, as assessed by the Independent Review Committee, was 5.36 months for ofatumumab and 3.61 months for physicians' choice (Hazard Ratio 0.79, p=0.267.Study (OMB114242) was conducted to meet the requirements from the EU Commission for the conditional approval of ofatumumab for the treatment of CLL in patients who are refractory to fludarabine and alemtuzumab. 

Company Quote

45.77
0.41 +0.90%
24 Oct 2014